Evaluation of 99mTc-erythromycin and 99mTc-streptomycin sulphate for the visualization of inflammatory lesions.
99mTc-erythromycin (E) and 99mTc-streptomycin sulphate (SS) were prepared with greater than 98% labelling efficiency. The labels were stable up to 24 h of testing, using ITLC-SG strips and acetone and saline as solvents. The biodistributions of both radiopharmaceuticals versus 67Ga-citrate were studied in mice with turpentine-induced abscesses at 6 days post-induction. The mice were sacrificed at 1, 3 and 6 h post-injection of 15 MBq of 99mTc-E or 99mTc-SS. Mice injected with 67Ga-citrate were sacrificed at 4 and 24 h. The maximum abscess-to-muscle ratios obtained by biodistribution studies were 2.36 +/- 1.04 (6 h), 2.38 +/- 0.38 (6 h) and 4.76 +/- 2.04 (4 h) with 99mTc-E, 99mTc-SS and 67Ga-citrate, respectively. The maximum abscess-to-contralateral tissue ratios by ROIs over respective areas on scintigrams were 2.38 +/- 0.16 (6 h), 3.21 +/- 0.14 (3 h) and 3.24 +/- 0.92 (24 h) for 99mTc-E, 99mTc-SS and 67Ga-citrate, respectively. The uptake mechanism might be infiltration into interstitial space due to increased capillary permeability.
Ercan
M T
MT
Department of Nuclear Medicine, Hacettepe University Medical Faculty, Ankara, Turkey.
Aras
T
T
Unsal
I S
IS
D000038:Abscess / Q000139:chemically induced / Q000000981:diagnostic imaging; D000818:Animals; D004917:Erythromycin / Q000493:pharmacokinetics*; D007249:Inflammation / Q000000981:diagnostic imaging*; D008297:Male; D051379:Mice; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D013307:Streptomycin / Q000493:pharmacokinetics*; D013667:Technetium / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D014425:Turpentine
D015609:Organotechnetium Compounds; C077318:technetium Tc 99m erythromycin; C077319:technetium Tc 99m streptomycin; D004917:Erythromycin; D013667:Technetium; D014425:Turpentine; D013307:Streptomycin